Myelodysplastic and myeloproliferative disorders of childhood.
Myelodysplastic and myeloproliferative disorders of childhood. Hematology Am Soc Hematol Educ Program. 2016 Dec 02;2016(1):598-604 Authors: Hasle H Abstract Myelodysplastic syndrome (MDS) and myeloproliferative disorders are rare in children; they are divided into low-grade MDS (refractory cytopenia of childhood [RCC]), advanced MDS (refractory anemia with excess blasts in transformation), and juvenile myelomonocytic leukemia (JMML), each with different characteristics and management strategies. Underlying genetic predisposition is recognized in an increasing number of patients. Germ line GATA2 mutation is found in 70% of adolescents with MDS and monosomy 7. It is challenging to distinguish RCC from aplastic anemia, inherited bone marrow failure, and reactive conditions. RCC is often hypoplastic and may respond to immunosuppressive therapy. In case of immunosuppressive therapy failure, hypercellular RCC, or RCC with monosomy 7, hematopoietic stem cell transplantation (HSCT) using reduced-intensity conditioning regimens is indicated. Almost all patients with refractory anemia with excess blasts are candidates for HSCT; children age 12 years or older have a higher risk of treatment-related death, and the conditioning regimens should be adjusted accordingly. Unraveling the genetics of JMML has demonstrated that JMML in patients with germ line PTPN11 and CBL mutations often regresses spontaneously, and therapy is seldom indicated. Conversely, patients with JM...
Without stem cells, new brain cells cannot be produced. • Try one of PsyBlog's ebooks, all written by Dr Jeremy Dean: Activate: How To Find Joy Again By Changing What You Do (NEW) The Anxiety Plan: 42 Strategies For Worry, Phobias, OCD and Panic Spark: 17 Steps That Will Boost Your Motivation For Anything
Condition: Hormone Deficiency Intervention: Combination Product: adipose-derived mesenchymal stem cells Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology Recruiting
Condition: Chronic Myeloid Leukemia Intervention: Biological: Chronic Myeloid Leukemia + NK cell Sponsor: Hospital de Clinicas de Porto Alegre Enrolling by invitation
Condition: Acute Myeloid Leukemia Intervention: Drug: Minnelide Sponsors: Justin Watts; Minneamrita Therapeutics LLC Not yet recruiting
Condition: Osteochondral; Defect Interventions: Procedure: autologous osteo-periosteal cylinder graft transplantation; Procedure: autologous osteochondral graft transplantation Sponsor: Peking University Third Hospital Not yet recruiting
Conditions: Pregnancy Complications; Anemia, Iron Deficiency; H Pylori Infection Interventions: Drug: triple attack therapy; Drug: Ferrous(II)-glycine-sulphate complex 567.7 mg capsules Sponsor: Kasr El Aini Hospital Not yet recruiting
With a rise in the prevalence of chronic wounds and other soft tissue defects, there is an urgent need to regenerate skin. Multilineage-differentiating stress-enduring cells were identified as distinct pluripotent stem cells in mesenchymal cell populations in humans. New research demonstrates the ability to effectively differentiate multilineage-differentiating stress-enduring cells into fibroblasts and keratinocytes for skin reconstitution.
By genetically altering a patient ’ s T-cells to attack more than one site on cancer cells, researchers hope to devise better treatments.
Conclusion: These data emphasize the significance of an early treatment response in achieving a DMR during dasatinib therapy.Oncology